Evaluation of Factors That Influence Dose Variability of Marek's Disease Vaccines.


Journal

Avian diseases
ISSN: 1938-4351
Titre abrégé: Avian Dis
Pays: United States
ID NLM: 0370617

Informations de publication

Date de publication:
12 2019
Historique:
received: 08 04 2019
accepted: 01 07 2019
entrez: 24 12 2019
pubmed: 24 12 2019
medline: 5 6 2020
Statut: ppublish

Résumé

Marek's disease (MD) vaccines are cell-associated and require special handling and care during administration. Vaccine dose is evaluated by plaque assay and is indicated as the number of plaque-forming units (PFUs) per dose. The objectives of this study were to evaluate the dose variability within each vial of MD vaccines and to assess those factors (from both manufacturing and handling and administration of the vaccine) that could affect vaccine dose variability. Three experiments were conducted. Experiment 1 was to evaluate dose variability in 36 MD vaccine vials and the effect of manufacturing factors on dose variability. Vaccines were titrated 10 times. Dose variability was measured as the coefficient of variability (CV) calculated as standard deviation divided by average PFU and multiplied by 100. Our results showed that all evaluated vaccines had levels of CV ranging from 10% to 34%. Variability existed regardless of manufacturer, vaccine serotype, and batch. Experiment 2 was conducted to evaluate the effect of infectivity rate (IR) on CV. IR was artificially reduced by adding noninfected chicken embryo fibroblast to the reconstituted vaccine before titration. Our results showed that decreased IR results in higher CV. Experiment 3 was to evaluate the handling and administration factors (time and mixing during administration) on CV. Our results showed that CV tends to increase with time and that this effect is more remarkable if vaccines were not mixed. Our study emphasizes the relevance of proper handling of MD vaccines and shows that dose variability can jeopardize the uniformity of vaccination in a flock and therefore the success of vaccination. Evaluación de factores que influyen en la variabilidad de las dosis de las vacunas contra la enfermedad de Marek. Las vacunas contra la enfermedad de Marek (MD) están asociadas a células y requieren un manejo y cuidado especiales durante la administración. La dosis de la vacuna se evalúa mediante un ensayo de placa y se indica como el número de unidades formadoras de placa (UFP) por dosis. Los objetivos de este estudio fueron evaluar la variabilidad de la dosis dentro de cada vial de vacunas contra la enfermedad de Marek y evaluar los factores (tanto de fabricación como de manipulación/administración de la vacuna) que podrían afectar la variabilidad de la dosis de la vacuna. Se realizaron tres experimentos. El experimento número 1 consistió en evaluar la variabilidad de la dosis en 36 viales de vacuna de Marek y el efecto de los factores de fabricación en la variabilidad de la dosis. Las vacunas fueron tituladas 10 veces. La variabilidad de la dosis se midió como el coeficiente de variación (CV) calculado como desviación estándar dividido por las UFP promedio y multiplicado por 100. Nuestros resultados mostraron que todas las vacunas evaluadas tenían coeficientes de variación que variaban del 10% al 34%. La variabilidad existía independientemente del fabricante, el serotipo de la vacuna y el lote. El experimento número 2 se realizó para evaluar el efecto de la tasa de infectividad (IR) en el coeficiente de variación. La tasa de infectividad se redujo artificialmente mediante la adición de fibroblastos de embrión de pollo no infectados a la vacuna reconstituida antes de la valoración. Los resultados mostraron que la disminución en la tasa de infectividad resulta en mayores coeficientes de variación. El experimento número 3 consistió en evaluar los factores de manipulación y administración (tiempo y mezclado durante la administración) sobre los coeficientes de variación. Nuestros resultados mostraron que el coeficiente de variación tiende a aumentar con el tiempo y que este efecto es más notable si las vacunas no se mezclan. Este estudio enfatiza la relevancia del manejo adecuado de las vacunas contra la enfermedad de Marek y muestra que la variabilidad de la dosis puede poner en peligro la uniformidad de la vacunación en una parvada y por lo tanto el éxito de la vacunación.

Autres résumés

Type: Publisher (spa)
Evaluación de factores que influyen en la variabilidad de las dosis de las vacunas contra la enfermedad de Marek. Las vacunas contra la enfermedad de Marek (MD) están asociadas a células y requieren un manejo y cuidado especiales durante la administración. La dosis de la vacuna se evalúa mediante un ensayo de placa y se indica como el número de unidades formadoras de placa (UFP) por dosis. Los objetivos de este estudio fueron evaluar la variabilidad de la dosis dentro de cada vial de vacunas contra la enfermedad de Marek y evaluar los factores (tanto de fabricación como de manipulación/administración de la vacuna) que podrían afectar la variabilidad de la dosis de la vacuna. Se realizaron tres experimentos. El experimento número 1 consistió en evaluar la variabilidad de la dosis en 36 viales de vacuna de Marek y el efecto de los factores de fabricación en la variabilidad de la dosis. Las vacunas fueron tituladas 10 veces. La variabilidad de la dosis se midió como el coeficiente de variación (CV) calculado como desviación estándar dividido por las UFP promedio y multiplicado por 100. Nuestros resultados mostraron que todas las vacunas evaluadas tenían coeficientes de variación que variaban del 10% al 34%. La variabilidad existía independientemente del fabricante, el serotipo de la vacuna y el lote. El experimento número 2 se realizó para evaluar el efecto de la tasa de infectividad (IR) en el coeficiente de variación. La tasa de infectividad se redujo artificialmente mediante la adición de fibroblastos de embrión de pollo no infectados a la vacuna reconstituida antes de la valoración. Los resultados mostraron que la disminución en la tasa de infectividad resulta en mayores coeficientes de variación. El experimento número 3 consistió en evaluar los factores de manipulación y administración (tiempo y mezclado durante la administración) sobre los coeficientes de variación. Nuestros resultados mostraron que el coeficiente de variación tiende a aumentar con el tiempo y que este efecto es más notable si las vacunas no se mezclan. Este estudio enfatiza la relevancia del manejo adecuado de las vacunas contra la enfermedad de Marek y muestra que la variabilidad de la dosis puede poner en peligro la uniformidad de la vacunación en una parvada y por lo tanto el éxito de la vacunación.

Identifiants

pubmed: 31865673
doi: 10.1637/aviandiseases-D-19-00097
doi:

Substances chimiques

Marek Disease Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

591-598

Références

Churchill AE, Payne LB, Chubb RC. Immunization against Marek's disease using a live attenuated virus.
Rispens BH, Van Vloten J, Mastenbroek N, Maas HJL, Schat KA. Control of Marek's disease in the Netherlands. I. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials.
Witter RL, Nazerian K, Purchase HG, Burgoyne GH. Isolation from turkeys of a cell-associated herpesvirus antigenically related to Marek's disease virus.
Morrow CJ, Fehler F. Marek's disease: a woldwide problem. In: Davison F, Nair V, eds.,
ICTVdB-Management. 00.031.1.03 Mardivirus. In: Buchen-Osmond C, ed.,
Witter RL. Characteristics of Marek's disease viruses isolated from vaccinated commercial chicken flocks: association of viral pathotype with lymphoma frequency.
Witter RL. Increased virulence of Marek's disease virus field isolates.
Witter RL, Calnek BW, Buscaglia C, Gimeno IM, Schat KA. Classification of Marek's disease viruses according to pathotype: philosophy and methodology.
Schat KA, Calnek BW. Characterization of an apparently nononcogenic Marek's disease virus.
Kawamura H, King DJ, Anderson DP. A herpesvirus isolated from kidney cell culture of normal turkeys.
Schat KA, Calnek BW, Fabricant J. Characterization of two highly oncogenic strains of Marek's disease virus.
Witter RL. Protection by attenuated and polyvalent vaccines against highly virulent strains of Marek's disease virus.
Marek's disease. In:
Darteil R, Bublot M, Laplace E, Bouquet JF, Audonnet JC, Riviere M. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens.
Goutebroze S, Curet M, Jay ML, Roux C, Le Gros FX. Efficacy of a recombinant vaccine HTV-VP2 against Gumboro disease in the presence of materna antibodies.
Perozo F, Villegas AP, Fernandez R, Cruz J, Pritchard N. Efficacy of single dose recombinant herpesvirus of turkey infectious bursal disease virus (IBDV) vaccination against a variant IBDV strain.
Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T, Mase M, Imada T, Yuasa N, Yamaguchi S. Complete, Long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens.
Esaki M, Godoy A, Rosenberger JK, Rosenberger SC, Gardin Y, Yasuda A, Dorsey KM. Protection and antibody response caused by turkey herpesvirus vector Newcastle disease vaccine.
Morgan RW, Gelb Jr J, Pope CR, Sondermeijer PJA. Efficacy in chickens of a herpesvirus of turkeys recombinant vaccine containing the fusion gene of Newcastle disease virus: onset of protection and effect of maternal antibodies.
Morgan RW, Gelb Jr J, Schreurs CS, Lutticken D, Rosenberger JK, Sondermeijer PJA. Protection of chickens from Newcastle and Marek's diseases with a recombinant herpesvirus of turkeys vaccine expressing the Newcastle disease virus fusion protein.
Palya V, Kiss I, Tatar-Kis T, Mato T, Felfoldi B, Gardin Y. Advancement in vaccination against Newcastle disease: recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions.
Johnson DI, Vagnozzi A, Dorea F, Riblet SM, Mundt A, Zavala G, Garcia M. Protection against infectious laryngotracheitis by in ovo vaccination with commercially available viral vector recombinant vaccines.
Vagnozzi A, Zavala G, Riblet SM, Mundt A, Garcia M. Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens.
Gardin Y, Palya V, Dorsey KM, El-Attrache J, Bonfante F, Wit S, Kapczynski D, Kilany WH, Rauw F, Steensels M, Soejoedono RD. Experimental and field results regarding immunity induced by a recombinant turkey herpesvirus H5 vector vaccine against H5N1 and other H5 highly pathogenic avian influenza virus challenges.
Rauw F, Palya V, Gardin Y, Tatar-Kis T, Dorsey KM, Lambrecht B, van den Berg T. Efficacy of rHVT-AI vector vaccine in broilers with passive immunity against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
Bublot M, Hurley-Bacon A, Hughes T, Sa e Silva M, Mebatsion T, Linz P, Pritchard N. Development of a new safe and efficacious Marek's disease vaccine containing a REV LTR insert in its genome. In: Desnesvre C, Bublot M, Vautherot JF, eds.,
Lupiani B, Lee LF, Kreager KS, Witter RL, Reddy SM. Insertion of reticuloendotheliosis virus long terminal repeat into the genome of CVI988 strain of Marek's disease virus results in enhanced growth and protection.
Calnek BW, Garrido C, Okazaki W, Patrascu IV. In vitro methods for assay of turkey herpesvirus.
Okazaki W, Purchase HG, Garrido C. The in vitro assay of the herpesvirus of turkeys.
U.S. Department of Agriculture. In: U.S. Department of Agriculture, ed., Animal and Plant Health Inspection Service Code of Federal Regulations. Washington, DC: Office of the Federal Register, part 113.330; 2018.
Gimeno, IM, Cortes AL, Faiz NM, Villalobos T, Badillo H, Barbosa T. Efficacy of various HVT vaccines (conventional and recombinant) against Marek's disease in broiler chickens: effect of dose and age of vaccination.
Gimeno, IM, Cortes AL, Montiel ER, Lemiere S, Pandiri AR. Effect of diluting Marek's disease vaccines on the outcomes of Marek's disease virus infection when challenge with highly virulent Marek's disease viruses.
Calnek BW. Influence of age at exposure on the pathogenesis of Marek's disease.
Eidson CS, Anderson DP. Optimum age for vaccinating chickens against Marek's disease.
Islam AF, Walkden-Brown SW, Groves PJ, Underwood GJ. Effects of vaccine dose, virus challenge dose and interval from vaccination to challenge on protection of broiler chickens against Marek's disease virus challenge.
Okazaki W, Burmester BR. The temporal relationship between vaccination with the herpesvirus of turkeys and challenge with virulent Marek's disease virus.
Spencer JL, Grunder AA, Robertson A, Speckmann GW. Attenuated Marek's disease herpesvirus: protection conferred on strains of chickens varying in genetic resistance.
Basarab O, Hall T. Comparisons of cell-free and cell-associated Marek's disease vaccines in maternally immune chicks.
Calnek BW, Smith MW. Vaccination against Marek's disease with cell-free turkey herpesvirus: interference by maternal antibody.
Spencer JL, Gavora JS, Grunder AA, Robertson A, Speckmann GW. Immunization against Marek's disease: influence of strain of chickens, maternal antibody and type of vaccine.
Dunn JR, Gimeno IM. Current status of Marek's disease in the United States and worldwide based on a questionnaire survey.
Gimeno IM. Future strategies for controlling Marek's disease. In: Nair V, Davison F, eds.,
Landman WJ, Verschuren SB. Titration of Marek's disease cell-associated vaccine virus (CVI 988) of reconstituted vaccine and vaccine ampoules from Dutch hatcheries.
Rispens BH, Van Vloten J, Mastenbroek N, Maas HJL, Hendrick JL. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus.
Gimeno IM, Cortes AL, Faiz NM, Barbosa T, Villalobos T. Evaluation of factors influencing efficacy of vaccine strain CVI988 against Marek's disease in meat-type chickens.
Geerligs HJ, Hoogendam A. Determination of optimal conditions for thawing and diluting cell-bound CVI 988 Marek's disease vaccine and stability of the diluted vaccine.
Halvorson DA, Mitchell DO. Loss of cell-associated Marek's disease vaccine titer during thawing, reconstitution and use.
Colwell WM, Simmons DG, Harris JR, Fulp TG, Carrozza JH, Maag TA. Influence of some physical factors on survival of Marek's disease vaccine virus.
Eidson CS, Page RK, Kleven SH. In vivo and in vitro studies on the effect of gentamicin sulfate on the efficacy of the turkey herpesvirus vaccine.

Auteurs

B A López de Juan Abad (BA)

Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, Raleigh, NC 27607.

A L Cortes (AL)

Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, Raleigh, NC 27607.

M Correa (M)

Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, Raleigh, NC 27607.

I M Gimeno (IM)

Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, Raleigh, NC 27607, imgimeno@ncsu.edu.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH